ArrayExpress Uploader0mouse5/6IL155/6IL155/6IL155/6IL155/6PBS- ip5/6PBS- ip5/6PBS- ip5/6PBS- ip5/6sham5/6sham5/6sham5/6sham5/6jak3i5/6jak3i5/6jak3i5/6jak3i5/6jak3i5/6jak12i5/6jak12i5/6jak12i5/6jak12i5/6jak12i5/6PBS- pump5/6PBS- pump5/6PBS- pump5/6PBS- gavage5/6PBS- gavage5/6PBS- gavage5/6PBS- gavage5/6PBS- gavage12/13IL1512/13IL1512/13IL1512/13jak3i12/13jak3i12/13jak3i12/13jak12i12/13jak12i12/13jak12i12/13PBS- ip12/13PBS- ip12/13PBS- ip12/13PBS- pump12/13PBS- pump12/13PBS- pump12/13PBS- gavage12/13PBS- gavage12/13PBS- gavage7224arrayexpress_sid6Our goal was to identify gene expression patterns that correlated with prevention of autoimmune alopecia in C3H/HeJ mice following...E-GEOD-45551/profile/8773/arrayexpressuploader248alopeciapointskinDec.12, 2014FalseE-GEOD-45551_A-AFFY-45prevention-of-mouse-aa-with-il-15-pathway-inhibitoPrevention of Mouse AA with IL-15 pathway inhibitorsNov.12, 2014Our goal was to identify gene expression patterns that correlated with prevention of autoimmune alopecia in C3H/HeJ mice following alopecic graft transplantation skin from 3-5 mice were taken at 5/6 weeks and 12/13 weeks of drug administration following grafting; mice were treated with ruxolitinib (jak12i) by oral gavage, tofacitinib (jak3i) by osmotic pump, antiIL15R-beta antibody by i.p. injection, or control pbs by either ip injection, oral gavage, or osmotic pump. sham indicates mice that received no graft. 3-5 biological replicates were taken at each time point for each treatment modalityhttp://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-45551http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-45551/samples/